A Case of Systemic Lupus Erythematosus Presenting as Malignant Hypertension with Hypertensive Retinopathy
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The variability of cardiovascular abnormalities is one of the characteristics of systemic lupus erythematosus (SLE). Among the cardiovascular manifestations, hypertension is reported in 14% to 58.1% of patients in diverse ethnic populations, and remains a clinically important issue due to its close relationship with early mortality in patients with SLE. The development of hypertension in patients with SLE has been associated with advanced lupus-related renal disease and the medications used for the treatment of lupus. Malignant hypertension is a serious complication of hypertension; it rarely occurs in patients with SLE. However, it can occur in patients with other complicated medical conditions such as the antiphospholipid antibody syndrome (APS) or cardiac tamponade. Here, we report the case of a patient with SLE and malignant hypertension with hypertensive retinopathy that initially presented without clinical evidence of APS or hypertensive nephropathy. (Korean J Intern Med 2010;25:341-344)
Abstract
The variability of cardiovascular abnormalities is one of the characteristics of systemic lupus erythematosus (SLE). Among the cardiovascular manifestations, hypertension is reported in 14% to 58.1% of patients in diverse ethnic populations, and remains a clinically important issue due to its close relationship with early mortality in patients with SLE. The development of hypertension in patients with SLE has been associated with advanced lupus-related renal disease and the medications used for the treatment of lupus. Malignant hypertension is a serious complication of hypertension; it rarely occurs in patients with SLE. However, it can occur in patients with other complicated medical conditions such as the antiphospholipid antibody syndrome (APS) or cardiac tamponade. Here, we report the case of a patient with SLE and malignant hypertension with hypertensive retinopathy that initially presented without clinical evidence of APS or hypertensive nephropathy. (Korean J Intern Med 2010;25:341-344)
참고문헌 (10)
- Ruiz-Irastorza G, "Systemic lupus erythematosus", Lancet, 357, pp.1027~1032 (2001)
- Keith NM, "The syndrome of malignant hypertension", Arch Intern Med, 41, pp.141~188 (1928)
- Yu SH, "Malignant hypertension: aetiology and outcome in 83 patients", Clin Exp Hypertens A, 8, pp.1211~1230 (1986)
- Jouquan J, "Accelerated hypertension associated with lupus anticoagulant and false-positive VDRL in systemic lupus erythematosus", Arthritis Rheum, 29, pp.147~ (1986)
- Tan EM, "The 1982 revised criteria for the classification of systemic lupus erythematosus", Arthritis Rheum, 25, pp.1271~1277 (1982)
- Shibagaki Y, "Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)", thrombotic thrombocytopenic purpura (TTP): can we differentiate one from the other?, 2005, pp.28, 89~95
- Budman DR, "Hypertension and renal disease in systemic lupus erythematosus", Arch Intern Med, 136, pp.1003~1007 (1976)
- Kaplan D, "Arthritis and hypertension in patients with systemic lupus erythematosus", Arthritis Rheum, 35, pp.423~428 (1992)
- Uthman I, "Antiphospholipid syndrome and the kidneys", Semin Arthritis Rheum, 35, pp.360~367 (2006)
- Giorgi D, "Retinopathy in systemic lupus erythematosus: pathogenesis and approach to therapy", Hum Immunol, 60, pp.688~696 (1999)